-

SAI MedPartners Expands Its Strategic Insights Capabilities Through Acquisition of Fulcrum Research Group

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce it has acquired Fulcrum Research Group (“Fulcrum”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022.

Fulcrum, founded in 2010 and based in Waltham, MA, is a primary market research consulting firm specializing in the healthcare and biopharmaceuticals markets. Fulcrum designs custom market research through direct physician and patient interviews and surveys to provide compelling insights to its clients. Specific areas of focus for Fulcrum include analysis of market dynamics, competitive advantages, product positioning, and the patient journey. Fulcrum’s leadership, including founders Erik Coats, Kelly Marino, and Lucy Robin, will remain in place following the transaction.

“We are thrilled to announce the addition of the Fulcrum team to SAI. Fulcrum and SAI share the same values and commitment to analytical research and top tier client service, so the fit is natural between the two organizations. Fulcrum complements SAI’s core competitive intelligence expertise and enhances our value proposition as a full-service decision support partner to the pharmaceutical and biotech sectors,” said Erik Nordhoy, Founder and CEO of SAI.

Erik Coats, Managing Partner of Fulcrum, commented “The Fulcrum team is excited to embark on this partnership. SAI is an ideal partner for the next stage of Fulcrum’s growth as it provides the opportunity to continue providing our best-in-class market research services, while also leveraging the capabilities and relationships of the SAI platform to augment our services to new and existing clients.”

Eugene Krichevsky, Partner at NCP, added, “This combination furthers our goal of building SAI into a premier global consultancy to the pharmaceutical and medical device industries. We look forward to continuing to strategically invest in resources to accelerate SAI’s growth and expand its service capabilities.”

ABOUT SAI MEDPARTNERS

SAI is a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Reading, Pennsylvania, SAI provides best-in-class competitive intelligence and strategy support services to assist its clients across the product development lifecycle. SAI works with leading multinational pharmaceutical companies, in addition to a growing number of biotechnology and medical device companies. SAI has a presence across the United States, Europe, and Asia. For more information, please visit www.sai-med.com.

ABOUT NORTHLANE CAPITAL PARTNERS

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested more than $1.6 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. For more information, please visit www.northlanecapital.com.

Contacts

SAI CONTACT

Erik Nordhoy, CEO
(610) 685-4204

NCP CONTACTS

Eugene Krichevsky, Partner
(301) 841-1399

Justin DuFour, Partner
(301) 841-1375

JJ Carbonell, Principal
(301) 841-1420

Anna Ellingboe, Vice President
(301) 272-9992

Northlane Capital Partners


Release Versions

Contacts

SAI CONTACT

Erik Nordhoy, CEO
(610) 685-4204

NCP CONTACTS

Eugene Krichevsky, Partner
(301) 841-1399

Justin DuFour, Partner
(301) 841-1375

JJ Carbonell, Principal
(301) 841-1420

Anna Ellingboe, Vice President
(301) 272-9992

More News From Northlane Capital Partners

SAI MedPartners Enhances Its Competitive Intelligence Capabilities Through the Acquisition of The Dunn Group

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired The Dunn Group (“TDG”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. TDG, headquartered in Totowa, NJ, is a competitive intelligence firm that focuses on providing primary business intelligence to clients in the pharmaceu...

Northlane Capital Partners Announces Final Close of Oversubscribed Fund III at $750 Million

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“Northlane” or “NCP”) announced today the final closing of its oversubscribed third private equity fund, Northlane Capital Partners III LP (“NCP III” or “Fund III”), at its hard cap of $750 million. The total raised substantially surpassed Fund III’s $550 million target and reflects notable growth from its $408 million predecessor. Global investors include pension funds, insurance companies, endowments and foundations, asset managers,...

Northlane Capital Partners Announces the Sale of Empower Community Care

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today the sale of Empower Community Care (“Empower” or the “Company”) to NexPhase Capital, LP (“NexPhase”). Founded in 2016, Empower is an established global behavioral health organization offering proprietary treatments and services to help at-risk youth, their families, and caregivers. The Company does not directly administer the treatment but instead provides its state and municipal clients with training and support...
Back to Newsroom